Marquee Middle Image

Faculty Profile

Rahul Parikh, M.D.

Dr. Rahul Parikh

Assistant Professor, Department of Radiation Oncology

 

Professional Interests

Rahul Parikh, MD, is a Radiation Oncologist at Continuum Cancer Centers of New York and an Attending Physician at Roosevelt Hospital & Beth Israel Medical Center. He specializes in the treatment of Lymphoma/Hematologic Malignancies and Brain tumors – benign & malignant. He works closely with a multidisciplinary team of highly skilled surgeons and medical oncologists to determine the best treatment options for his patients.

Dr. Parikh joined the department after completing his residency training in Radiation Oncology at UMDNJ-Robert Wood Johnson Medical School / The Cancer Institute of New Jersey where he held the title of Chief Resident Physician. He also completed his internship in preliminary internal medicine at UMDNJ. He received his medical degree from Albany Medical College in Albany, New York where he graduated with a distinction in research. His undergraduate education was received at Rensselaer Polytechnic Institute where he was graduated Magna Cum Laude from an accelerated physician-scientist (BS/MD) program.

Among his many accomplishments, Dr. Parikh has authored numerous abstracts and manuscripts, has received a number of research awards, and has guest lectured at several national and international meetings. He is a member of several professional organizations, including the American Society of Therapeutic Radiology & Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and Radiologic Society of North America (RSNA).

His clinical research interests focus on the integration of patient reported outcomes to improve cancer care delivery and the health-related quality of life in cancer patients. Also, his interests are to optimize the use of image-guided radiation therapy (IGRT), intensity-modulated radiation therapy (IMRT), stereotactic radiotherapy (SRT), and stereotactic radiosurgery (SRS) in the management of his cancer patients. He strives to provide state-of the-art treatment while working closely with his patients to provide quality care.

 

Selected Publications

Manuscripts:

R. R. Parikh, B. G. Haffty, D. Lannin, M. S. Moran.  Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation.  Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):7-13. Epub 2010 Oct 13.

N.K. Taunk, S. Goyal, M.S. Moran, Q. Yang, R.R. Parikh, B.G. Haffty.  Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy.  Radiother Oncol. 2010 Aug;96(2):204-8. Epub 2010 Mar 24.

R. R. Parikh, B. G. Haffty.  Local Therapy Matters; Editorial for: ‘Effective Local Therapy and Long Term Survival in Breast Cancer’ by K. M. Winkfield & J. R. Harris.  UMDNJ – Dept. of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women’s Harvard Medical School – Dept of Radiation Oncology.  Journal of Oncology.  2009 July 1.

S. Goyal, R. R. Parikh, C. Green, D. Schiff, M.S. Moran, Q. Yang, B.G. Haffty.  Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated with Breast-Conserving Surgery and Radiation Therapy.  Int J Radiat Oncol Biol Phys. 2009 May 21.

A. Rewari, H. Lu, R. R. Parikh, Q. Yang, Z. Shen , B. G. Haffty.  BCCIP as a prognostic marker for radiotherapy of laryngeal cancer.  The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School – Dept. of Radiation Oncology.  Radiotherapy and Oncology.  2008 Nov 27.

R. R. Parikh, D. Housman, Q. Yang, L. D. Wilson, B. G. Haffty.  Prognostic Value of Triple-Negative Phenotype at the Time of Locally Recurrent, Conservatively-treated Breast Cancer.  UMDNJ – Dept. of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, Yale University – Dept. of Therapeutic Radiology.  Int J of Radiat Oncol Biol Phys. 2008 Aug 1; [Epub ahead of print].     

R. R. Parikh, Q. Yang, S. A. Higgins, B. G. Haffty.  Outcomes In Young Women with Breast Cancer Of Triple-Negative Phenotype: The Prognostic Significance of CK19 Expression.  Int J of Radiat Oncol Biol Phys. 2007 Sept 11; [Epub ahead of print].

Parikh R. R., Yang Q., Haffty B. G.  Prognostic Significance of Vascular Endothelial Growth Factor protein levels in T1-2 N0 Laryngeal Cancer treated with Primary Radiation Therapy.  Cancer. 2007 Feb 1; 109(3):566-73.

Parikh R. R., Gildener-Leapman N, Narendran A, Lin HY, Lemanski N, Bennett JA, Jacobson HI, Andersen TT.  Prevention of N-Methyl-N-Nitrosourea-Induced Breast Cancer by α-Fetoprotein (AFP)-Derived Peptide, a Peptide Derived from the Active Site of AFP.  Clinical Cancer Research. 2005 Dec 1; 11(23): 8512-20.

R. R. Parikh, J.E. Tan, A. Nigam.  The use of a tissue expander to improve the therapeutic ratio of adjuvant radiotherapy for retroperitoneal sarcoma. AlbanyMedicalCollege, Depts. of Surgical Oncology & Radiation Oncology.  In Progress.

Abstracts:               

R. R. Parikh, A. J Khan, S. Goyal, S. Ahlawat, M. S. Moran, B. G. Haffty.  Extent of Axillary Dissection Predicts Survival in pN0 Early Stage Breast Cancer.  UMDNJ – Dept. of Radiation Oncology, Yale University – Dept. of Therapeutic Radiology.  American Society for Radiology and Oncology (ASTRO).  San Diego, CA.  November 2010.                    

R. R. Parikh, A. J Khan, S. Goyal, M. S. Moran, B. G. Haffty.  Tamoxifen Confers a Limited Benefit in Older Women with Early Stage Breast Cancer.  UMDNJ – Dept. of Radiation Oncology, Yale University – Dept. of Therapeutic Radiology.  American Society for Radiology and Oncology (ASTRO).  San Diego, CA.  November 2010.                    

R. R. Parikh, B. Patel, S. Jabbour, A. Cohler, V. Narra, B.G. Haffty, J. Nosher.  Yttrium-90 Microspheres for the Treatment of Unresectable Liver Tumors:  Comparison of Response by FDG-PET with CT.  UMDNJ – Depts. of Radiation Oncology and Interventional Radiology.  American Radium Society.  Cancun, MX.  May 2010.

R. R. Parikh, N. Taunk, M. S. Moran, B. G. Haffty.  Mucinous (colloid) Carcinoma of the Breast: Clincopathologic Features & Long-term Outcomes of Women treated with Breast-conserving Therapy.  UMDNJ – Dept. of Radiation Oncology, Yale University – Dept. of Therapeutic Radiology.  American Society for Therapeutic Radiology and Oncology (ASTRO).  Chicago, IL.  November 2009.                  

R. R. Parikh, A.J. Khan, M.S. Moran, B.G. Haffty.  Long-term Outcomes in Women with Early Stage Breast Cancer as a Function of Age.  UMDNJ – Dept. of Radiation Oncology,YaleUniversity – Dept. of Therapeutic Radiology.  American Radium Society. Vancouver,CA.  April 2009.

R. R. Parikh, B.G. Haffty, M.S. Moran.  Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation.  UMDNJ – Dept. of Radiation Oncology,YaleUniversity – Dept. of Therapeutic Radiology.  American Society for Therapeutic Radiology and Oncology (ASTRO). Boston,MA.  September 2008.                  

R. R. Parikh, D. Housman, Q. Yang, L. D. Wilson, B. G. Haffty.  Prognostic Value of Triple-Negative Phenotype at the Time of Locally Recurrent, Conservatively-treated Breast Cancer.  UMDNJ – Dept. of Radiation Oncology,MemorialSloan-KetteringCancerCenter,YaleUniversity – Dept. of Therapeutic Radiology.  American Society of Clinical Oncology (ASCO) – Breast Cancer Symposium. San Francisco, Ca.  September 2007.      

S. Shah, R. Yaparpalvi, R. Parikh, M. Garg, S. Kalnicki, M. Spierer, S. Mutyala.  Pilot Study to Asses the Feasibility of CT/MRI - Compatible Cervix Sleeve for Multiple Insertion High Dose Rate Image-Guided Brachytherapy (HDR-IGBT) in Cervix Cancer. MontefioreMedicalCenter,Bronx,NY.  Society of Gynecologic Oncologists (SGO). San Diego,CA.  March 2007.      

R. R. Parikh, Q. Yang, S. A. Higgins, B. G. Haffty.  Outcomes In Young Women with Breast Cancer Of Triple-negative (TN) Phenotype: The Prognostic Significance of CK19 Expression.  American Society for Therapeutic Radiology and Oncology (ASTRO). Philadelphia,PA.  November 2006.                  

R. R. Parikh, E. I. Cho, Q. Yang, B. G. Haffty.  Prognostic Significance of Vascular Endothelial Growth Factor protein levels in T1-2 N0 Laryngeal Cancer treated with Primary Radiation Therapy.  ASTRO – Translational Research in Radiation Oncology, Physics, and Biology Symposium. Boston,MA.  September 2006.

T.T. Andersen, J. Georgekutty, I. Anaka, R. R. Parikh, N. Gildener-Leapman, H.I. Jacobson, J.A. Bennett.  A Peptide that Prevents Breast Cancer is Fully Active after Oral Administration: AFPep.  AACR – Frontiers in Cancer Prevention Research. Baltimore,MD.  November 2005.

T.T. Andersen, R. R. Parikh, H.I. Jacobson, J.A. Bennett.  Safe and Effective Prevention of Breast Cancer by AFPep, an Active Site Peptide Analog of α-Fetoprotein.  AACR – Frontiers in Cancer Prevention Research. Phoeniz,AZ.  October 2003.

R. R. Parikh, D. Mcleod, F. Mesfin, L. DeFreest, H.I. Jacobson, J.A. Bennett, T.T. Andersen.  A Peptide Derived from the Active Site of Alpha-Fetoprotein Prevents Breast Cancer in a Rat Model.  AACR 94th Annual Meeting,Washington,DC.  July 2003.

T.T. Andersen, R. R. Parikh, F. Mesfin, L. DeFreest, H.I. Jacobson, J.A. Bennett.  Prevention of Breast Cancer by a Peptide Derived from the Active Site of α-Fetoprotein.  AACR – Frontiers in Cancer Prevention Research. Boston,MA.  October 2002. 

Book Chapters:

R. R. Parikh, B. G. Haffty (2008).  Chapter 10: Management of Local Recurrence.  In:  Breast Conservation Surgery: An Oncoplastic Approach, London, UK: Elsevier Limited. 

R. R. Parikh, H. Smith (2007).  Chapter 17: Radiopharmaceuticals.  In: McCleane G and Smith H, eds. Clinical Management of Bone & Joint Pain.Binghamton,New York: The Haworth Press, Inc.  (978-0-7890-3145-7).

 

More Information About Dr. Rahul Parikh

Continuum Cancer Centers of New York

Continuum Cancer Centers of New York

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Contact

Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center
1000 Tenth Avenue , Room LL
New York, NY 10019

Tel: 212.523.6630
Fax: 212.523.8189
rparikh@chpnet.org